Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.

BACKGROUND AIMS: The anti-CD52 monoclonal antibody alemtuzumab is employed in allogeneic hematopoietic cell transplantation (alloHCT) for the prevention of graft-versus-host disease (GVHD). However, its optimal dosing in this setting has not been determined yet. We compared three different alemtuzumab dose levels in reduced intensity conditioning (RIC) alloHCT with respect to lymphocyte recovery and outcome. METHODS: In 127 consecutive patients with predominantly advanced stage hematologic malignancies, a first alloHCT after RIC was performed, applying a fludarabine-based protocol (in 93% FBM: fludarabine, bis-chloroethyl-nitrosourea [BCNU], and melphalan). For GVHD prophylaxis, cyclosporine and alemtuzumab at three different dose levels (40 mg, 20 mg, 10 mg) were administered. Recovery of the peripheral blood (PB) lymphocyte sub-populations and clinical outcome were determined with regard to the alemtuzumab dose. RESULTS: Natural killer (NK) cell concentrations in PB around day +30 correlated inversely with the alemtuzumab dose, whereas other PB lymphocyte subtypes remained essentially unaffected by dosing of alemtuzumab. Lower alemtuzumab doses were associated with a tendency toward improved overall survival mainly during the early post-transplantation months. With regard to the PB NK cell concentration around day +30, "early intense NK cell reconstituters" tended to show an overall survival benefit. CONCLUSIONS: An alemtuzumab dose reduction to only 10-20 mg provides sufficient GVHD prophylaxis and supports improved NK cell regeneration early after alloHCT in PB ("NK cell saving effect"), which may have a positive effect on overall survival.

Patterned CoCrMo and Al2 O3 surfaces for reduced free wear debris in artificial joint arthroplasty.

Surface wear of corresponding tribological pairings is still a major problem in the application of artificial joint surgery. This study aims at developing wear reduced surfaces to utilize them in total joint arthroplasty. Using a pico-second laser, samples of medical CoCrMo metal alloy and Al2 O3 ceramic were patterned by laser material removal. The subsequent tribological investigations employed a ring-on-disc method. The results showed that those samples with modified surfaces show less mass or volume loss than those with a regular, smooth surface. Using calf serum as lubricating medium, the volume loss of the structured CoCrMo samples was eight times lower than that of regular samples. By structuring Al2 O3 surfaces, the wear volume could be reduced by 4.5 times. The results demonstrate that defined surface channels or pits enable the local sedimentation of wear debris. Thus, the amount of free debris could be reduced. Fewer abrasives in the lubricated so-called three-body-wear between the contact surfaces should result in less surface damage. Apart from direct influences on the wear behavior, less amounts of free debris of artificial joints should also be beneficial for avoiding undesired reactions with the surrounding soft tissues. The results from this study are very promising. Future investigations should involve the use of simulators meeting the natural conditions in the joint and in vivo studies with living organisms.

Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Danger signals released upon cell damage can cause excessive immune-mediated tissue destruction such as that found in acute graft-versus-host disease (GVHD), allograft rejection and systemic inflammatory response syndrome. Given that ATP is found in small concentrations in the extracellular space under physiological conditions, and its receptor P2X(7)R is expressed on several immune cell types, ATP could function as a danger signal when released from dying cells. We observed increased ATP concentrations in the peritoneal fluid after total body irradiation, and during the development of GVHD in mice and in humans. Stimulation of antigen-presenting cells (APCs) with ATP led to increased expression of CD80 and CD86 in vitro and in vivo and actuated a cascade of proinflammatory events, including signal transducer and activator of transcription-1 (STAT1) phosphorylation, interferon-γ (IFN-γ) production and donor T cell expansion, whereas regulatory T cell numbers were reduced. P2X(7)R expression increased when GVHD evolved, rendering APCs more responsive to the detrimental effects of ATP, thereby providing positive feedback signals. ATP neutralization, early P2X(7)R blockade or genetic deficiency of P2X(7)R during GVHD development improved survival without immune paralysis. These data have major implications for transplantation medicine, as pharmacological interference with danger signals that act via P2X(7)R could lead to the development of tolerance without the need for intensive immunosuppression.